P78.09 Immunotherapy Beyond Progression for Patients with Advanced Non-Small Cell Lung Cancer

Xiangwei Ge, Z. Zhang, Xinfeng Yan,F. Zhang,Yuan Fang,Han Xiao, Zhiyue Huang,Junxun Ma, L. Wang, Hai Tao, X. Li, Shaokai Zhang,Xiaoyu Zhi,Yi Hu, J. Wang

Journal of thoracic oncology（2021）

引用 0|浏览1

暂无评分

摘要

Immune checkpoint inhibitors (ICIs) have made a great breakthrough in the treatment of advanced non-small cell lung cancer (aNSCLC). However, whether immunotherapy beyond progression (IBP) is effective for aNSCLC still remains unknown. Therefore, we conducted a retrospective clinical study under real-world condition to investigate the efficacy of IBP for patients with aNSCLC and further identify the potential benefit subgroups patients.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要